This research study includes three visits for research blood, physical exam, and cardiac testing at baseline, 3 months, and 6 months. The study will collect the following data during the 6-month study period:~Blood sample collection~Electrocardiogram (ECG)~Echocardiogram~Cardiac magnetic resonance imaging (MRI)~Mobile cardiac telemetry~Blood pressure measurement
This is a multicenter, prospective, observational cohort study to comprehensively and longitudinally evaluate and characterizes the cardiovascular events with CLL patients who are initiating treatment with a Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or acalabrutinib.